DK3746126T3 - Fremgangsmåder og sammensætninger til behandling af søvnapnø eller simpel snorken - Google Patents

Fremgangsmåder og sammensætninger til behandling af søvnapnø eller simpel snorken Download PDF

Info

Publication number
DK3746126T3
DK3746126T3 DK19705634.4T DK19705634T DK3746126T3 DK 3746126 T3 DK3746126 T3 DK 3746126T3 DK 19705634 T DK19705634 T DK 19705634T DK 3746126 T3 DK3746126 T3 DK 3746126T3
Authority
DK
Denmark
Prior art keywords
compositions
methods
sleep apnea
treating sleep
simple snoring
Prior art date
Application number
DK19705634.4T
Other languages
Danish (da)
English (en)
Inventor
Lawrence G Miller
Barry Wohl
Walter J Lunsmann
Original Assignee
Apnimed Inc Delaware
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Apnimed Inc Delaware filed Critical Apnimed Inc Delaware
Application granted granted Critical
Publication of DK3746126T3 publication Critical patent/DK3746126T3/da

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/21Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/216Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/13Amines
    • A61K31/135Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/53751,4-Oxazines, e.g. morpholine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Emergency Medicine (AREA)
  • Pulmonology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
DK19705634.4T 2018-01-30 2019-01-30 Fremgangsmåder og sammensætninger til behandling af søvnapnø eller simpel snorken DK3746126T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862623892P 2018-01-30 2018-01-30
PCT/US2019/015781 WO2019152475A1 (en) 2018-01-30 2019-01-30 Methods and compositions for treating sleep apnea

Publications (1)

Publication Number Publication Date
DK3746126T3 true DK3746126T3 (da) 2024-10-07

Family

ID=65441079

Family Applications (1)

Application Number Title Priority Date Filing Date
DK19705634.4T DK3746126T3 (da) 2018-01-30 2019-01-30 Fremgangsmåder og sammensætninger til behandling af søvnapnø eller simpel snorken

Country Status (27)

Country Link
US (6) US11911351B2 (https=)
EP (2) EP3746126B1 (https=)
JP (3) JP7422666B2 (https=)
KR (2) KR20250156197A (https=)
CN (2) CN118384147A (https=)
AU (2) AU2019214891B2 (https=)
BR (1) BR112020015316A2 (https=)
CA (1) CA3089712A1 (https=)
DK (1) DK3746126T3 (https=)
EA (1) EA202091597A1 (https=)
ES (1) ES2991425T3 (https=)
FI (1) FI3746126T3 (https=)
HR (1) HRP20241412T1 (https=)
HU (1) HUE068505T2 (https=)
IL (1) IL276247A (https=)
LT (1) LT3746126T (https=)
MA (1) MA52861B1 (https=)
MD (1) MD3746126T2 (https=)
MX (2) MX2020008086A (https=)
PL (1) PL3746126T3 (https=)
PT (1) PT3746126T (https=)
RS (1) RS66104B1 (https=)
SG (1) SG11202007226UA (https=)
SI (1) SI3746126T1 (https=)
SM (1) SMT202400400T1 (https=)
UA (1) UA129618C2 (https=)
WO (1) WO2019152475A1 (https=)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2018260666B2 (en) 2017-04-28 2022-07-21 The Brigham And Women's Hospital, Inc. Methods and compositions for treating sleep apnea
EP4635514A3 (en) 2019-02-08 2025-12-24 The Brigham & Women's Hospital, Inc. Methods and compositions for treating sleep apnea
WO2021091902A1 (en) * 2019-11-04 2021-05-14 Apnimed, Inc. (Delaware) Combination pharmacological interventions for multiple mechanisms of obstructive sleep apnea
CN116391233A (zh) * 2020-09-30 2023-07-04 皇家飞利浦有限公司 用于执行剂量滴定的方法和系统
WO2022187420A1 (en) * 2021-03-04 2022-09-09 Apnimed, Inc. (Delaware) Combination of reboxetine and a muscarinic receptor antagonist (mra) for use in treating sleep apnea
GEAP202416361A (en) * 2021-03-24 2024-04-25 Apnimed Inc Delaware Methods and compositions for treating sleep apnea
WO2022235726A1 (en) 2021-05-04 2022-11-10 Apnimed, Inc. (Delaware) Solid forms of (r)-oxybutynin d-malate
KR20240021920A (ko) * 2021-06-17 2024-02-19 애프니메드, 인코포레이티드 (델라웨어) 수면 무호흡증을 치료하기 위한 노르에피네프린 재흡수 억제제
US20250049779A1 (en) 2021-12-22 2025-02-13 Bayer Aktiengesellschaft Combination of an a2-adrenoceptor subtype c (alpha-2c) antagonist with a norepinephrine reuptake inhibitor for the treatment of sleep apnea
MX2024007767A (es) 2021-12-22 2024-07-04 Bayer Ag Combinacion de un antagonista del adrenoceptor a2 subtipo c (alfa-2c) con un antagonista del receptor muscarinico para el tratamiento de la apnea del sue?o.
US20250302814A1 (en) * 2022-05-13 2025-10-02 Apnimed, Inc. (Delaware) Methods and compositions for treating sleep apnea
KR20250000641A (ko) * 2023-06-27 2025-01-03 주식회사 아스트로젠 수면장애 및/또는 수면장애 관련 질환을 예방, 개선 또는 치료하는 방법

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL267508A (https=) 1960-07-26
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
ES2268712T3 (es) 1995-10-24 2007-03-16 Grunenthal Gmbh Montirelina para inhibir la apnea del sueño.
PT1257277E (pt) 2000-02-24 2005-09-30 Pharmacia & Upjohn Co Llc Novas combinacoes de farmacos
US20020155113A1 (en) 2001-03-13 2002-10-24 Miyoung Chun Methods for treating or preventing cardiovascular disorders by modulating metalloprotease function
US20030060513A1 (en) 2001-09-27 2003-03-27 Arneric Stephen P. Pharmaceutical composition
US20030185882A1 (en) 2001-11-06 2003-10-02 Vergez Juan A. Pharmaceutical compositions containing oxybutynin
US20040235925A1 (en) 2002-12-17 2004-11-25 Pharmacia Corporation Method for the treatment, prevention, or inhibition of a CNS disorder and/or pain and inflammation using a combination of duloxetine, venlafaxine or atomoxetine and a cyclooxygenase-2 selective inhibitor and compositions thereof
US20050009862A1 (en) 2003-04-25 2005-01-13 Sabounjian Luann Method for promoting uninterrupted sleep by administration of trospium chloride
SG133606A1 (en) 2003-12-22 2007-07-30 Acadia Pharm Inc Amino substituted diaryl [a,d] cycloheptene analogs as muscarinic agonists and methods of treatment of neuropsychiatric disorders
US20060039867A1 (en) 2004-08-20 2006-02-23 Cypress Bioscience, Inc. Method for treating sleep-related breathing disorders with setiptiline
US8252321B2 (en) 2004-09-13 2012-08-28 Chrono Therapeutics, Inc. Biosynchronous transdermal drug delivery for longevity, anti-aging, fatigue management, obesity, weight loss, weight management, delivery of nutraceuticals, and the treatment of hyperglycemia, alzheimer's disease, sleep disorders, parkinson's disease, aids, epilepsy, attention deficit disorder, nicotine addiction, cancer, headache and pain control, asthma, angina, hypertension, depression, cold, flu and the like
WO2006055854A2 (en) 2004-11-17 2006-05-26 Cypress Bioscience, Inc. Methods for reducing the side effects associated with mirtazapine treatment
KR20070087678A (ko) 2004-12-20 2007-08-28 컬리지움 파마슈티칼, 인코포레이티드 수면 장애용 약제 조성물
CA2646729A1 (en) 2005-03-21 2006-09-28 Dov Pharmaceutical, Inc. Methods and compositions for the treatment of urinary incontinence
CA2603920A1 (en) 2005-04-15 2006-10-26 The Board Of Trustees Of The University Of Illinois Pharmacological treatment for sleep apnea
US20070021322A1 (en) 2005-07-21 2007-01-25 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Selective resonance of chemical structures
FR2889811B1 (fr) 2005-08-19 2009-10-09 Sanofi Aventis Sa Association d'un agent hypnotique a duree d'action longue et d'un agent hypnotique a duree d'action courte, composition pharmaceutique la contenant et son application en therapeutique.
ES2610508T3 (es) 2006-11-22 2017-04-27 Clinical Research Associates, Llc Métodos para tratar el síndrome de Down, el síndrome del cromosoma X frágil y el autismo
WO2008122019A1 (en) 2007-04-02 2008-10-09 Cypress Biosciences, Inc. Improving the tolerability of both mirtazapine and reboxetine by using them in combination
EP2455076A1 (en) 2007-04-09 2012-05-23 Sepracor Inc. Compositions comprising desvenlafaxine for use in treating sleep-related breathing disorders
US8415390B2 (en) 2008-05-30 2013-04-09 Microdose Therapeutx, Inc. Methods and compositions for administration of oxybutynin
US9119777B2 (en) 2008-05-30 2015-09-01 Microdose Therapeutx, Inc. Methods and compositions for administration of oxybutynin
US20090048233A1 (en) 2007-08-16 2009-02-19 Cypress Biosciences, Inc. Enhancing the Tolerability of a Seratonin Antagonist and a NSRI, a SNRI or a RIMA by Using Them in Combination
CN101925349A (zh) 2007-12-21 2010-12-22 欧兰德股份有限公司 替马西泮的口腔崩解片组合物
US20100204058A1 (en) 2009-01-28 2010-08-12 Howard Yuan-Hao Chang Profiling for Determination of Response to Treatment for Inflammatory Disease
CN102939008A (zh) 2010-04-01 2013-02-20 塞拉维达公司 改善睡眠质量的方法
CA2825309C (en) 2011-01-28 2019-10-01 Pfantastic Medical Research Institute, Llc Pyridostigmine for the treatment of obstructive sleep apnea
JP2012176958A (ja) 2012-04-20 2012-09-13 Watson Pharmaceuticals Inc (r)−オキシブチニンおよび(r)−デスエチルオキシブチニンによる平滑筋機能亢進の処置
US20160008334A1 (en) 2013-03-05 2016-01-14 Requis Pharmaceuticals Inc. Preparations for the Treatment of Sleep-Related Respiratory Disorders
WO2016062279A1 (zh) 2014-10-24 2016-04-28 朗齐生物医学股份有限公司 苹果酸丙氯陪拉辛锭用于制备治疗癌症药物的用途
DK3288946T3 (da) 2015-04-27 2019-11-25 Arena Pharm Inc 5-ht2c-receptoragonister og sammensætninger og anvendelsesfremgangsmåder
ES2925951T3 (es) 2015-07-22 2022-10-20 John Hsu Composición que comprende un agente terapéutico y un estimulante respiratorio y métodos para su uso
US20180235934A1 (en) 2015-08-18 2018-08-23 Massachusetts Institute Of Technology Noradrenergic drug treatment of obstructive sleep apnea
AU2018260666B2 (en) * 2017-04-28 2022-07-21 The Brigham And Women's Hospital, Inc. Methods and compositions for treating sleep apnea
MX2020007876A (es) 2018-01-31 2020-12-03 Res Inst Nationwide Childrens Hospital Terapia genica para la distrofia muscular de cinturas tipo 2c.
EP4635514A3 (en) 2019-02-08 2025-12-24 The Brigham & Women's Hospital, Inc. Methods and compositions for treating sleep apnea

Also Published As

Publication number Publication date
RS66104B1 (sr) 2024-11-29
KR20250156197A (ko) 2025-10-31
AU2019214891A1 (en) 2020-08-20
SMT202400400T1 (it) 2024-11-15
AU2024227631A1 (en) 2024-11-14
CA3089712A1 (en) 2019-08-08
HUE068505T2 (hu) 2024-12-28
EP4445951A3 (en) 2025-01-08
JP7422666B2 (ja) 2024-01-26
US20210038541A1 (en) 2021-02-11
CN118384147A (zh) 2024-07-26
EA202091597A1 (ru) 2020-10-22
SG11202007226UA (en) 2020-08-28
JP2021516218A (ja) 2021-07-01
ES2991425T3 (es) 2024-12-03
US11911351B2 (en) 2024-02-27
EP4445951A2 (en) 2024-10-16
MD3746126T2 (ro) 2024-12-31
MA52861A (fr) 2021-05-05
AU2019214891B2 (en) 2024-08-01
PL3746126T3 (pl) 2024-12-16
US20260027070A1 (en) 2026-01-29
US20220378724A1 (en) 2022-12-01
KR20200115598A (ko) 2020-10-07
US20250186371A1 (en) 2025-06-12
SI3746126T1 (sl) 2025-01-31
US20240156753A1 (en) 2024-05-16
MX2024001713A (es) 2024-02-20
IL276247A (en) 2020-09-30
UA129618C2 (uk) 2025-06-18
EP3746126A1 (en) 2020-12-09
FI3746126T3 (fi) 2024-10-10
JP2023181322A (ja) 2023-12-21
HRP20241412T1 (hr) 2024-12-20
WO2019152475A1 (en) 2019-08-08
PT3746126T (pt) 2024-10-21
MX2020008086A (es) 2021-02-15
EP3746126B1 (en) 2024-07-31
CN111670050A (zh) 2020-09-15
LT3746126T (lt) 2024-10-25
MA52861B1 (fr) 2024-09-30
BR112020015316A2 (pt) 2020-12-08
NZ766673A (en) 2025-08-29
KR102874891B1 (ko) 2025-10-21
US20240390299A1 (en) 2024-11-28
JP2025159230A (ja) 2025-10-17

Similar Documents

Publication Publication Date Title
DK3746126T3 (da) Fremgangsmåder og sammensætninger til behandling af søvnapnø eller simpel snorken
ZA201907158B (en) Methods and compositions for treating sleep apnea
DK4169491T3 (da) Indretninger og fremgangsmåde til behandling af bruxisme
DK3737765T4 (da) Forstærkede immunceller med dobbelt shrna og sammensætning dermed
DK3880660T3 (da) Forbindelser og sammensætninger til behandling af tilstande forbundet med nlrp-aktivitet
DK3402499T3 (da) Sammensætninger og fremgangsmåder til behandlingen af type 1 diabetes
EP3572400C0 (en) EZH2 INHIBITOR AND ITS USE
GB201501983D0 (en) Treatment of snoring and sleep apnoea
DK4014976T3 (da) Aprocitentan til anvendelse i behandlingen af hypertension og relaterede sygdomme i kombination med valsartan
DK3676285T3 (da) Vaccine til anvendelse i profylakse og/eller behandling af en sygdom
DK4104687T5 (da) Sammensætninger og fremgangsmåder til syntetisering af RNA'er med 5-kappe
DK3573630T3 (da) Forebyggelse og behandling af skader eller sygdom i knogler og brusk
DK3102189T3 (da) Sammensætning og fremgangsmåde til at fremme søvn
DK3164125T3 (da) Fremgangsmåder og sammensætninger til behandling af overvægt, forhindring af vægtforøgelse, fremme vægttab, fremme slankning eller behandling eller forebyggelse af udvikling af diabetes
DK3362449T3 (da) Sibirilin-derivater til anvendelse til at forebygge og/eller behandle lidelser associeret med cellulær nekroptose
DK3444010T3 (da) Pklr-inhibering i behandlingen af nafld og hcc
DK3790879T3 (da) Triazolopyrimidinforbindelser og deres anvendelse til behandling af kræft
DK3807316T3 (da) Sammensætninger og fremgangsmåder til behandling af cancer
IL285197A (en) Methods and preparations for the treatment of sleep apnea
DK3522873T3 (da) Sammensætninger og fremgangsmåder til behandlingen af xerostomi
DK3510870T3 (da) Fødevarehylster med antimykotiske egenskaber og fremgangsmåde til fremstilling deraf
DK3529234T3 (da) Forbindelser, fremgangsmåde til opnåelse af forbindelserne, farmaceutisk sammensætning, anvendelse af forbindelserne og fremgangsmåde til behandling af psykiatriske lidelser og/eller søvnforstyrrelser
DK3519411T3 (da) Heterocykliske forbindelser og deres anvendelse inden for forebyggelsen eller behandlingen af bakterieinfektioner
DK3373922T3 (da) Sammensætninger og fremgangsmåder til anvendelse i behandlingen af homocystinuri
IL281455A (en) Methods and apparatus for inducing or modifying sleep